Traditional Chinese medicine enema for treating non-alcoholic steatohepatitis as well as preparation method and application method of traditional Chinese medicine enema

Abstract

The invention discloses a traditional Chinese medicine enema for treating non-alcoholic steatohepatitis as well as a preparation method and application method of the traditional Chinese medicine enema. The traditional Chinese medicine enema consists of the following raw material drugs: herba artemisiae scopariae, radix paeoniae rubra, radix salviae miltiorrhizae, flos carthami, semen persicae, radix bupleuri, radix paeoniae alba, rheum officinale, radix scutellariae, radix astragali, poria cocos, roasted rhizome atractylodis macrocephalae, rhizoma corydalis and fructus toosendan. The drugs aredirectly absorbed through intestinal mucosae by virtue of a retention enema method based on a ''gut-liver axis'' theory, so that damage caused by gastric acid and digestive juice to the drugs is reduced, and the utilization rate of drugs is increased; toxic metabolites and toxins in enteric cavities and on the intestinal mucosae can be directly eliminated, intestinal florae can be regulated, thesituation that toxic substances enter livers through enterohepatic circulation can be avoided, clinical symptoms and signs of patients can be effectively relieved, liver functions and blood lipid parameters of can be reduced, the intestinal florae can be improved, and the non-alcoholic steatohepatitis can be effectively prevented and treated. Besides, the traditional Chinese medicine enema can beindependently used and can be combined with other drugs and treatment methods for use.

Description

technical field [0001] The invention relates to a traditional Chinese medicine enema for treating non-alcoholic steatohepatitis and its preparation method and application method, in particular to a traditional Chinese medicine enema for preventing and treating non-alcoholic steatohepatitis and non-alcoholic liver fibrosis combination agent. Background technique [0002] Nonalcoholic fatty liver disease (NAFLD) is a metabolic stress-induced liver injury closely associated with insulin resistance and genetic susceptibility, including nonalcoholic hepatic steatosis, nonalcoholic steatohepatitis (NASH), cirrhosis and Hepatocellular carcinoma (HCC). With the improvement of living standards and changes in dietary structure, NAFLD has gradually become the chronic liver disease with the highest incidence in my country. NASH is an intermediate stage of simple fatty liver progressing to liver cirrhosis and HCC, and it is difficult to recover on its own. In NASH patients, the liver f...

AI Technical Summary

Problems solved by technology

[0005] Although in the prior art, Chinese patents (patent publication numbers CN 105833179A and CN 110339252A) all disclose traditional Chinese medicines for the treatment of nonalcoholic steatohepatitis, most of the existing Chinese medicine compounds for the treatment of nonalcoholic steatohepatitis are oral preparations. Although there is a certain curative effect, due to the gastrointestinal congestion, endotoxin stimulation, intestinal flora imbalance and gastrointestinal dysfunction in patients with liver disease, they usually show more digestive tract symptoms. Intestinal irritation is great, and some patients will aggravate gastrointestinal symptoms after taking the medicine, making it difficult to adhere to treatment

Moreover, the oral preparations are destroyed by gastric acid and digestive juice, the blood drug concentration decreases, and the amount of drug entering the liver through systemic circulation is limited, resulting in low drug utilization.

Images